Global state: non‐responders to the first injection · psychosis‐induced aggression or agitation (rapid tranquillisation)
ARIPIPRAZOLE (IM) showed no clear difference in global state: non‐responders to the first injection compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (low certainty).
1 finding from 1 review
Repeated need for tranquillisation ‐ needing additional injections during 24 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes repeated need for tranquillisation ‐ needing additional injections… compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review
Global state: non‐responders to the first injection · psychosis‐induced aggression or agitation (rapid tranquillisation)
ARIPIPRAZOLE (IM) may leads to lower global state: non‐responders to the first injection compared with PLACEBO/NIL (low certainty).
1 finding from 1 review
Repeated need for tranquillisation ‐ needing additional injections during 24 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes repeated need for tranquillisation ‐ needing additional injections… compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (very low certainty).
1 finding from 1 review
Repeated need for rapid tranquillisation ‐ needing additional injection during 24 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes repeated need for rapid tranquillisation ‐ needing additional… compared with COMBINATIONS: b. HALOPERIDOL + LORAZEPAM (very low certainty).
1 finding from 1 review
Repeated need for rapid tranquillisation ‐ more than 1 injection · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes repeated need for rapid tranquillisation ‐ more that 1 injection compared with OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE (very low certainty).
1 finding from 1 review
Repeated need for tranquillisation ‐ needing additional injections during 24 hours · patients with psychosis‐induced aggression or agitation
HALOPERIDOL may leads to lower repeated need for tranquillisation needing additional injection… compared with PLACEBO/NIL (low certainty).
1 finding from 1 review
Repeated need for rapid tranquillisation ‐ more than 1 injection · psychosis‐induced aggression or agitation
HALOPERIDOL probably leads to higher repeated need for rapid tranquillisation ‐ more than 1 injection compared with OTHER ANTIPSYCHOTIC: c. DROPERIDOL (moderate certainty).
1 finding from 1 review
Repeated need for rapid tranquillisation ‐ more than 3 injections · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes repeated need for rapid tranquillisation ‐ more than 3 injections compared with OTHER ANTIPSYCHOTIC: k. ZUCLOPENTHIXOL ACETATE (very low certainty).
1 finding from 1 review
Repeated need for rapid tranquillisation ‐ needing additional injection · patients with psychosis‐induced aggression or agitation
HALOPERIDOL may leads to lower repeated need for rapid tranquillisation ‐ needing additional… compared with OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE (low certainty).
1 finding from 1 review
Repeated need for rapid tranquillisation ‐ more than 1 injection · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes repeated need for rapid tranquillisation more than 1 injection compared with BENZODIAZEPINE: b. LORAZEPAM (very low certainty).
1 finding from 1 review
Global state: 2. Requiring 3 or more injections ‐ over 7 days · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE may leads to lower global state: 2. Requiring 3 or more injections ‐ over 7 days compared with STANDARD DRUG CARE (low certainty).
1 finding from 1 review
Global state: 2. Requiring 3 or more injections ‐ over 7 days · patients with acute schizophrenia and similar serious mental illnesses
1 finding from 1 review
Global outcome: Number of additional injections ‐ 2‐4 injections · patients with psychosis‐induced aggression or agitation
It is very uncertain whether CHLORPROMAZINE changes global outcome: Number of additional injections ‐ 2‐4 injections compared with HALOPERIDOL (very low certainty).
1 finding from 1 review
Global outcome: Number of additional injections ‐ 5 or more · patients with psychosis‐induced aggression or agitation
It is very uncertain whether CHLORPROMAZINE changes global outcome: Number of additional injections ‐ 5 or more compared with HALOPERIDOL (very low certainty).
1 finding from 1 review
Death by end of trial · patients with schizophrenia
Paliperidone palmitate showed no clear difference in death Reported by trial author compared with risperidone long‐acting injection (low certainty).
1 finding from 1 review
No clinically important change Number of people whose PANSS score either increased or did not decrease by at least 30% from the beginning to the end of the trial · patients with schizophrenia
Paliperidone palmitate showed no clear difference in no clinically important change Number of people whose PANSS score… compared with risperidone long‐acting injection (low certainty).
1 finding from 1 review
Relapse: recurrence of psychotic symptoms Reported by trial author as adverse event · patients with schizophrenia
Paliperidone palmitate showed no clear difference in relapse: recurrence of psychotic symptoms Reported by trial authors… compared with risperidone long‐acting injection (moderate certainty).
1 finding from 1 review
Cost ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health related quality of life ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found